216 related articles for article (PubMed ID: 31833956)
1. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma.
Mourah S; Louveau B; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):91-97. PubMed ID: 31833956
[TBL] [Abstract][Full Text] [Related]
2. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
[TBL] [Abstract][Full Text] [Related]
3. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
4. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
5. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
6. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma.
Almeida FV; Douglass SM; Fane ME; Weeraratna AT
Pigment Cell Melanoma Res; 2019 Mar; 32(2):237-247. PubMed ID: 30216694
[TBL] [Abstract][Full Text] [Related]
7. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
8. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma.
Mangin MA; Boespflug A; Maucort Boulch D; Vacheron CH; Carpentier I; Thomas L; Dalle S
Cancer Med; 2021 May; 10(10):3155-3164. PubMed ID: 33932099
[TBL] [Abstract][Full Text] [Related]
9. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
10. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
13. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.
Tarhini A; Kudchadkar RR
Cancer Treat Rev; 2018 Dec; 71():8-18. PubMed ID: 30273812
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
15. Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.
Chacon AC; Melucci AD; Qin SS; Prieto PA
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33810078
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
17. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
[TBL] [Abstract][Full Text] [Related]
18. Many ways to resistance: How melanoma cells evade targeted therapies.
Kozar I; Margue C; Rothengatter S; Haan C; Kreis S
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):313-322. PubMed ID: 30776401
[TBL] [Abstract][Full Text] [Related]
19. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.
Seyhan AA; Carini C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613491
[TBL] [Abstract][Full Text] [Related]
20. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
Mandalà M; Massi D
Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]